Precision Medicine

A new FDA approval for Roche's HER2 tests paves the way for a powerful new drug, offering hope to patients with aggressive gastroesophageal adenocarcinoma.

A landmark study reveals that children of centenarians inherit a powerful biological advantage, rewriting our understanding of aging, health, and longevity.

A new partnership merges genetic screening and sperm analysis, promising empowered family planning. But as data deepens, are we crossing an ethical frontier?

From stroke pioneer to lung disease disruptor, Brainomix's new AI studies signal a major shift in diagnostics. This is the story behind the numbers.

FDA clearance for Roche's pTau217 blood test isn't just a clinical win; it's a strategic move to dominate a $27B market by making diagnosis simple and scalable.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

The ALS Association's premier conference unites patients, researchers, and advocates to tackle the disease from the lab bench to the insurance appeal.

An AI tool just received FDA clearance to quantify Alzheimer's biomarkers in brain scans. It promises earlier answers, but raises profound questions for patients and our healthcare system.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

Fannin Partners secures key grants to advance its Raptamer therapy for a rare pediatric cancer, highlighting a funding model vital for high-risk innovation.

A biotech startup's nomination for a top award validates its unique platform, which uses a patient's own cells to fight cancer and prepare for future pandemics.

How a startup, once dismissed as 'too niche,' leveraged deep science to achieve 1,624% growth, proving the microbiome is the next frontier of medicine.

With a second Inc. 5000 nod and XPRIZE validation, AgelessRx is proving that aging well is more than a trend—it's a high-growth industrial sector.

Amprion's expansion of its alpha-synuclein test to Europe isn't just a deal; it's the build-out of a new infrastructure for understanding the brain.

RyboDyn's RyboCypher platform is uncovering a 'dark proteome' full of tumor-specific targets, promising a new era beyond today's crowded drug pipeline.

As BioPorto preps its H1 2026 results, its promising NGAL kidney test faces a crucial moment. Can it sustain growth and appease a global market?

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

NeuroPace reports strong Q2 growth and raises 2026 guidance, driven by its RNS system. A new AI tool and key clinical data signal a deeper push into personalized medicine.

OTraces' new AI analyzes biological 'noise' to forecast Type 1 Diabetes with over 92% accuracy, promising a new era of early intervention and care.